Hepatitis B Virus Prevalence and Mother-to-Child Transmission Risk in an HIV Early Intervention Cohort in KwaZulu-Natal, South Africa

Jane Millar,1 Gabriela Z. L. Cromhout,2,3 Noxolo Mchunu,2 Nomonde Bengu,2,4 Thumbi Ndung’u,2,5,6 Philip J. Goulder,1 Philippa C. Matthews,5,7,8 and Anna L. McNaughton2,9

1Department of Paediatrics, University of Oxford, Oxford, UK, 2HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu Natal, Durban, South Africa, 3Department of Paediatrics and Child Health, University of KwaZulu Natal, Durban, South Africa, 4Department of Paediatrics, Queen Nandi Regional Hospital, Empangeni, South Africa, 5Africa Health Research Institute, Durban, South Africa, 6Division of Infection and Immunity, University College London, London, UK, 7The Francis Crick Institute, London, UK, 8Department of Infectious Diseases, University College London Hospital, London, UK, and 9Nuffield Department of Medicine, University of Oxford, Oxford, UK

Background. HIV and hepatitis B virus (HBV) prevalence are both high in KwaZulu-Natal, South Africa. HIV coinfection negatively affects HBV prognosis and can increase the likelihood of HBV mother-to-child transmission (MTCT). In an early HIV infant treatment intervention cohort of HIV-transmitting mother-child pairs in KwaZulu-Natal, we characterized maternal HBV prevalence and screened infants at risk.

Methods. Infants were treated for HIV MTCT at birth, and combination regimens incidentally active against HBV were initiated within 21 days. Maternal samples (N = 175) were screened at birth for HBV infection (HBV surface antigen [HBsAg]), exposure to HBV (HBV anti-core IgG), and vaccination responses (HBV anti-S positive without other HBV markers). Infants of mothers who were HBV positive were screened for HBsAg at 1 and 12 months.

Results. Evidence of HBV infection was present in 8.6% (n = 15) of maternal samples. Biomarkers for HBV exposure were present in 31.4% (n = 55). Evidence of HBV vaccination was uncommon in mothers (8.0%; n = 14). Despite prescription of antiretroviral therapy (ART) active against HBV, HBV DNA was detectable in 46.7% (7/15) of mothers who were HBsAg positive. Three mothers had HBV viral loads >5.3 log10 IU/mL, making them high risk for HBV MTCT. Screening of available infant samples at 1 month (n = 14) revealed no cases of HBV MTCT. At 12 months, we identified 1 HBV infection (1/13), and serologic evidence of vaccination was present in 53.8% (7/13) of infants.

Discussion. This vulnerable cohort of HIV-transmitting mothers had a high prevalence of undiagnosed HBV. Early infant ART may have reduced the risk of MTCT in high-risk cases. Current HBV guidelines recommend ART prophylaxis, but these data underline the pressing need to increase availability of birth dose vaccines.

Keywords. antiretroviral therapy; hepatitis B virus; HIV; PMTCT; South Africa.

The World Health Organization Africa region bears a disproportionate burden of global hepatitis B virus (HBV), with an estimated 75 million individuals chronically infected in the region [1], of whom 2.6 million are living with HBV/HIV coinfection [2]. The KwaZulu-Natal (KZN) province in South Africa (SA) has a high HIV prevalence, reported as 40.9% in a 2019 national antenatal survey [3]. HBV prevalence in KZN was estimated to be 4.0% in a 2019 household survey, although prevalence was >2-fold higher among people living with HIV [4]. HBV coinfection can negatively affect HBV outcomes, with approximately 2.5-fold greater risk of HBV mother-to-child transmission (MTCT) [5, 6]. However, individuals with coinfection potentially benefit from shared treatment with nucleos/tide analogues active against both viruses, including lamivudine (3TC), tenofovir disoproxil fumarate (TDF), and emtricitabine [7, 8]. Antiretroviral therapy (ART) is recommended throughout pregnancies for women living with HIV, and this may also suppress HBV infection, mitigating MTCT risk [8].

High maternal HBV viral load (VL) and positive HBV e-antigen (HBeAg) status increase the risk of HBV MTCT [2]. World Health Organization guidelines advocate that nucleos/tide analogue treatment be started between weeks 24 and 28 of gestation when the maternal HBV VL is >5.3 log10 IU/mL [9]. Additional interventions are recommended, including HBV immunoglobulin in selected infants, alongside universal birth dose vaccine for neonates (given within the first 24 hours...
of life) [10]. HIV MTCT in SA has drastically reduced in recent years [11] and is most common in vulnerable individuals with the least interaction with health care. To investigate the impact of HIV coinfection and its treatment on HBV MTCT in KZN, we retrospectively screened maternal and infant serum samples from a cohort in which HIV MTCT was documented.

**METHODS**

**Cohort and Management of HIV and HBV Infections**

We retrospectively tested a cohort in which in utero HIV MTCT was documented from the Ucwaningo Lwabantwana (Learning From Children) study, established in KZN in 2015, to examine the impact of early initiation of combination ART (cART) on HIV infection in infants [12]. Local HIV/ HBV management guidelines were adhered to [13, 14]. Mothers initiated lifelong ART at HIV diagnosis, but incomplete adherence to ART was typical [12]. All first-line treatments were cART, including at least 1 HBV active agent (typically TDF).

Infants were treated within 48 hours of life for HIV MTCT and switched to cART within 21 days. 3TC was included in all infant cART. Clinical data and blood samples from the mother-child pairs were collected at enrollment (within 21 days of delivery), monthly for 6 months, then every 6 months thereafter. Samples from the mothers were tested for HBV serology at birth, and infant 1- and 12-month samples were screened for HBV. Infants in this cohort should have received HBV immunization as part of a multivalent vaccine schedule starting at age 6 to 10 weeks but were unlikely to have received birth dose vaccination. HBV immunoglobulin is not routinely available in SA.

**HBV Serology Testing**

Maternal HBV infection was determined by the presence of HBV surface antigen (HBsAg) and previous infection by the presence of total HBV anti-core IgG (anti-HBc) without HBsAg. Mothers were screened for anti-HBc IgM, which can be an indicator of recent infection. HBV vaccination was assumed if HBV anti-S (anti-HBs) was present in the absence of any other HBV biomarker (Supplementary Table 1). Samples testing HBsAg positive were further tested for HBeAg and HBV DNA quantification to determine risk of MTCT (Supplementary Figure 1 for testing approach). Infant samples were screened for HBsAg if the maternal sample was HBsAg positive. If at either time point they were HBsAg positive, HBV DNA was also tested. Anti-HBs was assessed in infants at 12 months of age who were at risk to determine vaccine-mediated immunity.

HBV testing was carried out by Neuberg Global Laboratories. Higher risk of MTCT was assumed in mothers who were HBeAg positive or had HBV DNA >5.3 log\textsubscript{10} IU/mL [9]. Maternal age, ART, HIV VL, and CD4 count were recorded during the Ucwaningo Lwabantwana study [12]. Statistical analysis was performed via Stata version 16.1 (StataCorp) and Prism version 9.4 (GraphPad) with Kruskal-Wallis tests to determine statistical differences between groups.

**Ethics and Patient Consent Statement**

The study was approved by the KZN Bioethics Research Ethics Committee and the Oxfordshire Research Ethics Committees (BF450/14). Written informed consent for the infant and mother’s participation in the study was obtained from the mother or infant’s legal guardian. Maternal study identifications (IDs) were anonymized for publication.

**RESULTS**

**High Maternal HBsAg Prevalence Is Present in This Population**

This study included 175 mothers who were HIV positive, sampled between July 2015 and April 2021, of whom 15 (8.6%) were HBsAg positive (Figure 1A) at the time of delivery. Among these, 3 (20%) were not recorded as undergoing ART during pregnancy, with the other 12 receiving ART for varying amounts of time (Table 1). However, as evidenced by HIV MTCT in all cases, ART was inconsistent due to the diverse social vulnerabilities in these women, as previously described [15]. HBeAg-positive status was not associated with HIV VL or T-cell counts (Supplementary Figure 2), and women who were HBsAg positive were younger than women who were HBsAg negative (mean, 21.7 vs 25.5 years; Supplementary Table 2).

**High Risk of HBV MTCT Is Present Despite Prescription of HBV-Active ART**

Among the 15 mothers testing HBsAg positive, 4 (26.7%) were HBeAg positive and 7 (46.7%) were HBV DNA positive at delivery (Table 1, Figure 1C). All women who were HBsAg positive had detectable HBV DNA; of these, 3 of 4 women had VL classified as high risk for MTCT (Figure 1D). CD4+ T-cell counts were lower in women testing HBV DNA positive than in their counterparts who were virologically suppressed (263.7 vs 643.0 cells/mm\textsuperscript{3}; Supplementary Table 2). One mother (ID HBKN-118) had an HBV VL of 6.6 log\textsubscript{10} IU/mL and was aviremic for HIV (Table 1), indicating a similar clinical phenotype to previously reported cases of HBV drug resistance in SA where suppression of HIV is a proxy for adequate adherence to therapy [16].

**Other Maternal HBV Biomarkers**

Approximately a third of mothers in the study were anti-HBc positive (32.0%, 56/175), indicating serologic evidence of exposure to HBV. However, among the HBsAg-positive samples, only 7 of 15 (46.7%) were anti-HBc IgG positive. One mother was anti-HBc IgM, anti-HBs, and anti-HBc IgG positive, potentially suggesting recent exposure and clearance or reactivation.
Anti-HBs was detected in 33.1% mothers (58/175) (Figure 1). Anti-HBs was rare among the women who were HBsAg positive, with just 3 (20%) of these women testing anti-HBs positive. These women were all anti-HBc positive and HBeAg negative, and HBV DNA was below the limit of detection. Only 14 of 58 women had an anti-HBs–only profile, reflecting a low prevalence of vaccine-mediated immunity, at just 8.0% in the cohort overall (Figure 1B). The presence of anti-HBs and anti-HBc was not associated with HIV VL or T-cell counts (Supplementary Figures 3, 4).

HBV Detected in 1 Infant at Age 12 Months in a Mother With Detectable HBV and HIV Viraemia at Birth

All screened infants were HBV negative at 1 month (n = 14; no sample for 1 infant), and 1 of 13 (7.7%) infants was HBV positive at 12 months of age. At birth, the mother of the infant who was HBV positive was HBeAg negative, with an HBV VL of 3.8 log_{10} IU/mL, and was recorded as taking TDF-based therapy throughout pregnancy but had a detectable HIV VL of 5.6 log_{10} copies/mL. Of note, this infant did not receive 3TC containing cART until 21 days of life, as compared with the overall median of 6.5 days (IQR, 2.3–12.8) among other infants. Despite the ongoing prescription of cART, at 12 months the infant had an HIV VL >8.0 log_{10} HIV RNA copies/mL and did not achieve HIV plasma viral suppression until 18 months of age, suggesting poor adherence. HBV infection was not detected in any of the infants of the mothers deemed high transmission risk, although 1 mother-child pair (maternal ID HBKN-05) was lost of follow-up after initial enrollment. The infant from the mother who was anti-HBc IgM positive was also screened at 1 and 12 months, and both these infant samples tested negative (Table 1).

Infants With Vertical HIV Infection Have a Low Rate of Vaccine-Mediated Immunity to HBV Infection

All available 12-month infant samples that were screened for HBsAg were screened for anti-HBs (n = 13; including the infant of the mother who was IgM positive) to look for evidence of HBV vaccination (Table 1). An anti-HBs–only serologic profile was observed in 7 of 13 (53.8%) infants. The infant who was HBsAg positive also tested anti-HBs positive (1/13), and the remaining samples were anti-HBs negative (5/13). This suggests that 7 of 13 infants in this cohort received infant vaccination, although we cannot exclude the possibility that partial vaccination series were delivered or that, despite vaccination, anti-HBs titers were not mounted due to HIV coinfection.
Table 1. Maternal HBV and HIV Virology and Serology Results Among Mother-Child Paired Samples Who Were HBsAg (n = 15) and Anti-HBc IgM (n = 1) Positive

<table>
<thead>
<tr>
<th>Maternal Study ID</th>
<th>Anti-HBs</th>
<th>Anti-HBc</th>
<th>HBeAg</th>
<th>VL Log_{10} IU/mL</th>
<th>HBV MTCT Risk</th>
<th>Proportion of Pregnancy on ART, %</th>
<th>HBV Active NA in Maternal Treatment</th>
<th>Maternal HIV VL Log_{10} Copies/mL</th>
<th>CD4 Cells/mL</th>
<th>CD8 Cells/mL</th>
<th>Infant HBsAg, 1 month</th>
<th>Infant HBsAg, 12 months</th>
<th>Infant Anti-HBs, 12 months</th>
<th>Infant PMTCT at Birth</th>
<th>Infant cART Initiation, days</th>
</tr>
</thead>
<tbody>
<tr>
<td>HBKN-109</td>
<td>+</td>
<td>+ [IgM+]</td>
<td>N/A</td>
<td>1.94</td>
<td>Low</td>
<td>Unclear</td>
<td>TDF</td>
<td>3.3</td>
<td>653</td>
<td>1554</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>AZT/3TC/AZT/NVP</td>
<td>8–14</td>
</tr>
<tr>
<td>HBKN-26</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>1.94</td>
<td>Low</td>
<td>69.5</td>
<td>TDF</td>
<td>&lt;1.30</td>
<td>479</td>
<td>1069</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>NVP/AZT/AZT/3TC/AZT/NVP</td>
<td>≤7</td>
</tr>
<tr>
<td>HBKN-61</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>&lt;1.92</td>
<td>Low</td>
<td>65.9</td>
<td>TDF</td>
<td>&lt;1.30</td>
<td>552</td>
<td>1358</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>AZT/NVP/AZT/3TC/AZT/NVP</td>
<td>8–14</td>
</tr>
<tr>
<td>HBKN-62</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>&lt;1.92</td>
<td>Low</td>
<td>4.9</td>
<td>TDF</td>
<td>3.53</td>
<td>481</td>
<td>1717</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>≤7</td>
</tr>
<tr>
<td>HBKN-99</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>3.8</td>
<td>Low</td>
<td>6.3</td>
<td>TDF</td>
<td>2.93</td>
<td>1183</td>
<td>946</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>NVP/AZT/3TC/AZT/NVP</td>
<td>8–14</td>
</tr>
<tr>
<td>HBKN-100</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>&lt;1.92</td>
<td>Low</td>
<td>0.0</td>
<td>TDF</td>
<td>4.59</td>
<td>606</td>
<td>1349</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>NVP/AZT/3TC/AZT/NVP</td>
<td>≤7</td>
</tr>
<tr>
<td>HBKN-103</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>&lt;1.92</td>
<td>Low</td>
<td>0.0</td>
<td>TDF</td>
<td>3.45</td>
<td>437</td>
<td>2213</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>NVP/AZT/3TC/AZT/NVP</td>
<td>≤7</td>
</tr>
<tr>
<td>HBKN-114</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>&lt;1.92</td>
<td>Low</td>
<td>100.0</td>
<td>TDF</td>
<td>5.11</td>
<td>770</td>
<td>806</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>AZT/3TC/AZT/NVP/AZT</td>
<td>≤7</td>
</tr>
<tr>
<td>HBKN-117</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>&lt;1.92</td>
<td>Low</td>
<td>2.9</td>
<td>TDF</td>
<td>4.84</td>
<td>726</td>
<td>1154</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>AZT/3TC/AZT/NVP/AZT</td>
<td>≤7</td>
</tr>
<tr>
<td>HBKN-149</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>&lt;1.92</td>
<td>Low</td>
<td>12.4</td>
<td>TDF</td>
<td>4.95</td>
<td>333</td>
<td>1273</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>NVP/3TC/NVP/AZT</td>
<td>8–14</td>
</tr>
<tr>
<td>HBKN-160</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>&lt;1.92</td>
<td>Low</td>
<td>0.0</td>
<td>TDF</td>
<td>&lt;1.30</td>
<td>389</td>
<td>967</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>AZT/3TC/AZT/NVP</td>
<td>8–14</td>
</tr>
<tr>
<td>HBKN-72</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>2.78</td>
<td>Low</td>
<td>57.5</td>
<td>3TC</td>
<td>4.08</td>
<td>50</td>
<td>442</td>
<td>–</td>
<td>NS</td>
<td>–</td>
<td>NS/3TC/AZT/NVP/AZT</td>
<td>≤7</td>
</tr>
<tr>
<td>HBKN-95</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>&gt;8.22</td>
<td>High</td>
<td>100.0</td>
<td>TDF</td>
<td>5.40</td>
<td>252</td>
<td>777</td>
<td>–</td>
<td>NS</td>
<td>–</td>
<td>NS/3TC/AZT/NVP/AZT</td>
<td>≤7</td>
</tr>
<tr>
<td>HBKN-118</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>6.62</td>
<td>High</td>
<td>53.8</td>
<td>TDF</td>
<td>&lt;1.30</td>
<td>292</td>
<td>722</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>AZT/NVP/3TC/AZT/3TC/NVP</td>
<td>15–21</td>
</tr>
<tr>
<td>HBKN-159</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>7.49</td>
<td>High</td>
<td>100.0</td>
<td>TDF</td>
<td>4.60</td>
<td>109</td>
<td>375</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>AZT/3TC/AZT/NVP</td>
<td>≤7</td>
</tr>
</tbody>
</table>

HBV MTCT risk was based on maternal HBV viral load, with the World Health Organization threshold >5.3 log_{10} IU/mL used to identify high risk pregnancies. [9] One sample (HBKN-109) tested HBsAg negative and anti-HBc IgM positive and interpretation was unclear, so samples from the paired infant were screened. One mother-child pair had no infant samples available for testing at either time point; another sample had insufficient volume at 12 months; and another was lost to follow-up.

Abbreviations: anti-HBc, HBV anti-core IgG; anti-HBs, HBV anti-S; ART, antiretroviral therapy; cART, combination ART; HBsAg, HBV surface antigen; HBV, hepatitis B virus; MTCT, mother-to-child transmission; N/A, not applicable; NA, nucleos/tide analogue; NS, no sample available; PMTCT, prevention of MTCT; VL, viral load.

Maternal treatments included TDF (tenofovir) or 3TC (lamivudine).

Infant HIV PMTCT included AZT (zidovudine) and/or NVP (nevirapine). cART also included 3TC, ritonavir-boosted lopinavir (referred to as Kaletra [KAL]), and abacavir (ABC).

The study aimed to prescribe infant cART within 21 days of life.
DISCUSSION

A high HBV prevalence (8.6%) was observed in this vulnerable cohort of mothers. Among the coinfected group, 20% were classified as high risk for HBV MTCT based on virologic parameters, reaching this threshold despite the availability of ART active against HBV. Despite these risks, all infants in the cohort from mothers infected with HBV tested HBV negative at birth.

A single HBV infection was identified in an infant at 12 months of age, born to a mother who was not classified as high risk. However, women with HIV/HBV coinfection should be prescribed ART regardless of HBV VL, and poorly controlled HIV infection is itself a risk factor for HBV transmission in this case. It is noteworthy that the majority of data informing these guidelines stem from Asia and that studies in Africa have documented HBV MTCT with a lower HBV VL and in women who are HBeAg negative. It is possible this early infant intervention for neonates with HIV may have minimized HBV MTCT events in this cohort.

Serologic evidence of maternal HBV vaccination was low at 8.0%. However, it is possible that a higher proportion of infants remain at risk of horizontal transmission later in childhood. Previous work has shown that vaccinated infants who are HIV positive typically produce protective anti-HBs titers until approximately 1 year of age but that titers wane rapidly in the following years, suggesting that infants without responses in our study had missed or incomplete vaccine courses. Our data underscore the importance of (1) combining antenatal HBV screening with maternal prophylaxis and (2) starting infant vaccination with a timely birth dose vaccine and follow-up doses during infancy.

Serologic evidence of maternal HBV vaccination was low at just 8.0%. However, it is possible that a higher proportion received childhood vaccination but that vaccine-mediated antibody titers had waned over time in the context of HIV infection. Anti-HBc IgG is assumed to persist for life, making it useful for population-based screening. Over half the women who were HBsAg positive in this cohort were anti-HBc negative, with recent infection unlikely, suggesting that HIV infection is compromising the generation of anti-HBc antibodies in these women. This serologic profile has been described in other coinfected cohorts associated with HIV (especially with low CD4 counts) and in patients undergoing solid organ transplants, suggesting an association with immune compromise. In populations where HIV is endemic, screening based on anti-HBc may therefore underestimate the proportion of the population exposed.

Women who tested HBsAg positive were on average 4 years younger than other women in the cohort, suggesting that younger women were particularly vulnerable to HBV MTCT. Previous research has indicated that adolescent and younger mothers are generally less engaged with the HIV continuum of care for the prevention of MTCT than older women, placing their infants at greater risk of HIV and HBV infection.

Limitations

The number of women in the study who were HBV positive was small, with a single mother-child case of HBV MTCT identified, making findings difficult to generalize. HBV sequencing to confirm linkage in the mother-child pair would have been helpful, but this was not feasible: both had relatively low HBV DNA (~3.0 log_{10} IU/mL), which makes sequencing challenging. Sequencing would also have been informative to better understand the clinical phenotype in the mother who had undetectable HIV but a high HBV VL.

Occult HBV, where individuals are HBsAg negative but HBV DNA positive, has been reported to be more common among individuals who are HIV positive. The testing algorithm used in our study did not screen for occult HBV, and it is therefore possible that numerous HBV cases were overlooked. Further work on the prevalence of occult HBV and the potential risk of HBV MTCT in these cases would be informative, but HBV DNA testing remains costly relative to serologic testing, limiting widespread use in resource-poor settings.

CONCLUSIONS

Our study indicates a high HBV prevalence among mothers living with HIV in KZN, putting their pregnancies at risk of HBV MTCT. It is important to avoid complacency in assuming that prescription of ART active against HIV and HBV prevents against transmission events. However, maternal ART and the early ART treatment of infants likely contributed to reducing the chances of infant HBV infections in mothers at high risk. A role for the increased use of maternal prophylaxis and potential neonatal postexposure prophylaxis in infants at high risk should be considered in addition to robust vaccination (birth dose and follow-up in infancy). Interdisciplinary interventions are required to support disadvantaged women who are at high risk of MTCT to enhance screening, treatment, and prophylaxis. These interventions are crucial to support progress toward international elimination goals for HBV.

Supplementary Data

Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Notes

Author contributions. All authors contributing to the study were given the opportunity to comment on the manuscript and approved the final submitted version of the manuscript.
Acknowledgments. We would like to acknowledge all the women and their infants who have participated in the Ucwaningo Lwabantwana (Learning From Children) study over the years and the many health care workers who have supported the families throughout.

Data availability. HBV serology data for all 175 mothers and infants tested as a part of the study are available on Figshare: https://doi.org/10.6084/m9.figshare.22259224.

Financial support. This study was funded by an Oxford University John Fell Fund award (0008410) held by A. L. M. Supplementary testing was funded by the Wellcome Trust. P. C. M. is funded by Wellcome (grant 110110/Z/15/Z), the Francis Crick Institute, and UCLH Biomedical Research Centre.

Potential conflicts of interest. All authors: No reported conflicts.

References